What Questions Can Large, Simple Trials Answer?
- 1 March 1998
- journal article
- review article
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 8 (Suppl. 2) , 30-36
- https://doi.org/10.1159/000047509
Abstract
Large, simple trials can provide reliable evidence on the balance of risk and benefit of widely practicable treatments that have moderate effects on major clinical outcomes. Treatments for stroke will potentially be used extensively world-wide. Each year about 8,000,000 people have an acute stroke, with about 5,000,000 being ischaemic. Of these, perhaps 1,000,000 receive medical attention within the first few hours of stroke onset. If reliable decisions about the treatment of such large numbers of patients are to be made, we need to be certain about the effects of treatment on death from any cause (and on other important outcomes) and in many different types of patient. Generally, such reliable evidence on whether to treat and on whom to treat, will only come from large, randomised trials recruiting many thousands of patients. Such trials are only feasible and affordable if they are simple.Keywords
This publication has 7 references indexed in Scilit:
- CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic strokeThe Lancet, 1997
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic strokePublished by Elsevier ,1997
- Mortality by cause for eight regions of the world: Global Burden of Disease StudyPublished by Elsevier ,1997
- Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsPublished by Elsevier ,1994
- MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosisThe Lancet, 1991